

1 **The impact of emerging *Plasmodium knowlesi* on accurate diagnosis by light microscopy: a**  
2 **systematic review and modelling analysis**

3

4 John H. Huber, Margaret Elliott, Cristian Koepfli, T. Alex Perkins

5

6 Department of Biological Sciences and Eck Institute for Global Health, University of Notre

7 Dame, Notre Dame, IN, USA

8

9 Corresponding Author: [huber.j.h@wustl.edu](mailto:huber.j.h@wustl.edu) (JHH)

10 Alternative Corresponding Author: [taperkins@nd.edu](mailto:taperkins@nd.edu) (TAP)

11

12 Keywords: *Plasmodium knowlesi*; misdiagnosis; light microscopy; systematic review;

13

14 Summary: Co-circulation of *Plasmodium* species parasites may limit the accuracy of malaria

15 diagnosis by light microscopy. Variation in performance of light microscopy is highly correlated

16 with the prevalence of the parasites in the epidemiological setting.

17

## 18 **ABSTRACT**

### 19 **Background**

20 The five *Plasmodium* spp. that cause human malaria appear similar under light microscopy,  
21 which raises the possibility that misdiagnosis could routinely occur in clinical settings. Assessing  
22 the extent of misdiagnosis is of particular importance for monitoring *P. knowlesi*, which co-  
23 circulates with the other *Plasmodium* spp.

### 24 **Methods**

25 We performed a systematic review and meta-analysis of studies comparing the performance of  
26 microscopy and PCR for diagnosing malaria in settings with co-circulation of the five  
27 *Plasmodium* spp. We assessed the extent to which co-circulation of *Plasmodium* parasites affects  
28 diagnostic outcomes. We fit a Bayesian hierarchical latent class model to estimate variation in  
29 microscopy sensitivity and specificity.

### 30 **Results**

31 Mean sensitivity of microscopy was low, yet highly variable across *Plasmodium* spp., ranging  
32 from 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum* and 40.3% (22.0 – 61.5%) for *P. vivax* to  
33 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 – 22.0%) for *P. malariae*, and 0.180%  
34 (0.00491 – 1.21%) for *P. ovale*. Observed PCR prevalence was positively correlated with  
35 estimated microscopic sensitivity and negatively correlated with estimated microscopic  
36 specificity, though the strength of the associations varied by species.

### 37 **Conclusions**

38 Our analysis suggests that co-circulation of *Plasmodium* spp. undermines the accuracy of  
39 microscopy. Sensitivity was considerably lower for *P. knowlesi*, *P. malariae*, and *P. ovale*. The  
40 negative association between specificity and PCR prevalence imply that less frequently

41 encountered species may be misdiagnosed as more frequently encountered species. Together,  
42 these results suggest that the burden of *P. knowlesi*, *P. malariae*, and *P. ovale* may be  
43 underappreciated in a clinical setting.

44

## 45 INTRODUCTION

46 *Plasmodium falciparum* and *Plasmodium vivax* are the predominant parasites responsible for  
47 human malaria worldwide, causing an estimated 193.9 million and 14.3 million clinical cases in  
48 2017, respectively [1,2]. Given their contribution to the global burden of malaria, *P. falciparum*  
49 and *P. vivax* remain the primary focus of public health efforts aimed at achieving malaria  
50 elimination and eradication [3]. However, three additional *Plasmodium* species—*P. knowlesi*, *P.*  
51 *malariae*, and *P. ovale*—also cause clinical episodes of malaria, though their overall burden  
52 remains uncertain due in part to routine misdiagnosis in a clinical setting [4].

53         Diagnosis of clinical malaria is routinely performed using light microscopy (LM). In  
54 addition to challenges presented by low or submicroscopic parasite densities [5], accurate  
55 speciation of malaria parasites using LM depends upon identification of morphological features  
56 characteristic of the *Plasmodium* spp. causing the infection. However, morphological similarities  
57 across the five *Plasmodium* spp., such as the resemblance of early blood-stage *P. knowlesi*  
58 parasites to *P. falciparum* parasites and late blood-stage *P. knowlesi* parasites to *P. malariae*  
59 parasites [3,6], undermine species-level identification of *Plasmodium* infections [7].

60         In settings with co-circulation of the *Plasmodium* spp., routine misdiagnosis by light  
61 microscopy has consequences for clinical decision-making and malaria control. The choice of  
62 therapeutic is specific to the *Plasmodium* spp. causing the infection [8], so misdiagnosis may  
63 lead to ineffective treatment of blood-stage parasites for all *Plasmodium* spp. infections as well  
64 as ineffective or no treatment of liver-stage parasites for *P. vivax* and *P. ovale* infections.  
65 Additionally, misdiagnosis may present challenges for monitoring *Plasmodium* spp.  
66 transmission, particularly for the emerging zoonosis *P. knowlesi*. Currently, the extent of human-  
67 to-human transmission of *P. knowlesi* is unknown [3,9], and misdiagnosis could cause

68 transmission clusters to appear smaller than their actual size, leading to an underestimate of  
69 transmission [10].

70 Consequently, measuring the extent of misdiagnosis by light microscopy is of importance  
71 to public health, and past studies have directly compared the diagnostic performance of light  
72 microscopy to polymerase chain reaction (PCR) in settings with co-circulation of *Plasmodium*  
73 spp. parasites [7,11–22]. However, these studies varied in their criteria for enrollment and other  
74 study design features, as well as in the epidemiological settings in which they were conducted.  
75 This makes direct comparison of their estimates of diagnostic performance challenging.

76 To synthesize across these studies, we performed a systematic review and meta-analysis  
77 of the diagnostic performance of light microscopy in settings with co-circulation of all five  
78 *Plasmodium* spp. We identified studies that compared the diagnostic performance of light  
79 microscopy to PCR and fit a hierarchical Bayesian latent class model to estimate study-level and  
80 species-level sensitivities and specificities of light microscopy. Finally, to assess whether the  
81 perceived prevalences of the five species might affect diagnostic outcomes of light microscopy,  
82 we explored the relationship between the estimates of sensitivity and specificity that we obtained  
83 and the observed PCR prevalences in each study.

84

## 85 **METHODS**

### 86 **Search Strategy and Selection Criteria**

87 In this systematic review and meta-analysis, JHH searched MEDLINE and Web of Science for  
88 studies published in English before April 30<sup>th</sup>, 2020 that compared the diagnostic performance of  
89 light microscopy (LM) and polymerase chain reaction (PCR) for *Plasmodium* spp. infections.  
90 We identified studies using the following search strategy: (*Plasmodium* OR malaria) AND

91 *knowlesi* AND ((microscopy OR microscopic OR blood film OR thick film OR thin film) AND  
92 (PCR or “polymerase chain reaction”)).

93         Studies met the criteria for inclusion if they compared the performance of LM and PCR  
94 on clinical samples collected in areas with endemic transmission of all five *Plasmodium* spp. that  
95 naturally infect humans (i.e., *P. falciparum*, *P. vivax*, *P. knowlesi*, *P. malariae*, and *P. ovale*).  
96 Furthermore, studies were only included if they used a PCR protocol that was capable of  
97 amplifying DNA from all five *Plasmodium* spp. Prior to 2004, the public health burden of *P.*  
98 *knowlesi* was underappreciated [6], so restricting our search to studies published between 2004  
99 and 2021 ensured that the diagnostic outcomes were representative of the current clinical and  
100 diagnostic landscape.

101         The data were extracted from each study that met the criteria for inclusion. Because the  
102 data in each study was anonymized and reported in aggregate, ethical approvals were not  
103 required according to a determination from the University of Notre Dame Institutional Review  
104 Board that this study did not constitute human subjects research.

105

## 106 **Data Analysis**

### 107 *Overview*

108 To model the diagnostic performance of LM and PCR, we constructed a Bayesian hierarchical  
109 latent class model of clinical diagnosis [23]. In this model, the probability  $p_{ijkl}$  of obtaining LM  
110 outcome  $i \in \{1,0\}$  and PCR outcome  $j \in \{1,0\}$  for *Plasmodium* spp.  $k$  in study  $l$  is

111

$$p_{ijkl} = \begin{cases} se_{LM}^{(k,l)} se_{PCR}^{(k,l)} \theta_k^{(l)} + (1 - sp_{LM}^{(k,l)}) (1 - sp_{PCR}^{(k,l)}) (1 - \theta_k^{(l)}), & i = 1, j = 1 \\ se_{LM}^{(k,l)} (1 - se_{PCR}^{(k,l)}) \theta_k^{(l)} + (1 - sp_{LM}^{(k,l)}) sp_{PCR}^{(k,l)} (1 - \theta_k^{(l)}), & i = 1, j = 0 \\ (1 - se_{LM}^{(k,l)}) se_{PCR}^{(k,l)} \theta_k^{(l)} + sp_{LM}^{(k,l)} (1 - sp_{PCR}^{(k,l)}) (1 - \theta_k^{(l)}), & i = 0, j = 0 \\ (1 - se_{LM}^{(k,l)}) (1 - se_{PCR}^{(k,l)}) \theta_k^{(l)} + sp_{LM}^{(k,l)} sp_{PCR}^{(k,l)} (1 - \theta_k^{(l)}), & i = 0, j = 0 \end{cases} \quad (1)$$

112

113 In eq. (1),  $se_{LM}^{(k,l)}$  and  $sp_{LM}^{(k,l)}$  are the sensitivity and specificity of LM for *Plasmodium* spp.  $k$  in

114 study  $l$ ,  $se_{PCR}^{(k,l)}$  and  $sp_{PCR}^{(k,l)}$  are the sensitivity and specificity of PCR for *Plasmodium* spp.  $k$  in

115 study  $l$ , and  $\theta_k^{(l)}$  is the prevalence of *Plasmodium* spp.  $k$  among participants in study  $l$ . In many

116 cases,  $\theta_k^{(l)}$  is not equivalent to community prevalence, due to characteristics of the study

117 participants that are not representative of the surrounding community.

118 A key assumption of the latent class model is that diagnostic outcomes are conditionally

119 independent. That is, by assuming that the sensitivity and specificity of a given diagnostic

120 method is unique for each *Plasmodium* spp., the outcome that we observe for one parasite

121 species using a given diagnostic method is modelled as independent of the outcomes observed

122 for all other parasite species and diagnostic methods. This implies that the probability of a set of

123 diagnostic outcomes observed across all five *Plasmodium* spp. is equal to the product of the

124 probabilities of the diagnostic outcome for each *Plasmodium* spp. Nevertheless, the assumption

125 of conditional independence still allows for interactions between *Plasmodium* spp. that arise in

126 the context of misdiagnosis. For example, if a *P. knowlesi* infection is misdiagnosed as a *P.*

127 *malariae* infection using LM, then the sensitivity of LM for *P. knowlesi* and the specificity of

128 LM for *P. malariae* are penalized, because both a false-negative *P. knowlesi* diagnosis and a

129 false-positive *P. malariae* diagnosis occurred.

130

### 131 *Accounting for Differences in Study Design*

132 Studies identified in the systematic review varied by enrollment and diagnostic criteria. Where  
133 enrollment in a study required a positive *Plasmodium* spp. diagnosis by LM or PCR, we  
134 normalized the probabilities of eq. (1), such that they were consistent with the subset of possible  
135 diagnostic outcomes that could be observed with that study design.

136 Because *P. knowlesi* and *P. malariae* share morphological similarities [3,6], studies may  
137 diagnose samples as “*P. knowlesi* / *P. malariae*” with LM, indicating that the microscopist  
138 identified *P. knowlesi* and/or *P. malariae* parasites in the sample but could not make a more  
139 precise mono-infection or co-infection diagnosis. To accommodate this in our model, we defined  
140 parameters  $se_{LM}^{("Pk/Pm"|Pk,l)}$  and  $se_{LM}^{("Pk/Pm"|Pm,l)}$  as the sensitivities of LM to diagnose samples in  
141 study  $l$  as “*P. knowlesi* / *P. malariae*”, given that the samples contained *P. knowlesi* and *P.*  
142 *malariae* parasites, respectively.

143

### 144 *Inference*

145 Using PCR as the gold standard, we fit a hierarchical latent class model of clinical diagnosis to  
146 the studies identified in our systematic review to estimate study-level and species-level variation  
147 in LM sensitivity and specificity for each *Plasmodium* spp. We fit our model in a Bayesian  
148 framework using Stan by running four independent chains of 2,000 samples, each with a warm-  
149 up period of 1,000 samples [24]. We tested for convergence with the Gelman-Rubin statistic and  
150 pooled the independent chains for a posterior distribution of 4,000 samples. Supplementary  
151 analyses were performed to evaluate the sensitivity of our posterior estimates to the inclusion of  
152 each study and to the assumption of PCR as the gold standard. See the Supporting Information  
153 for more details.




154

155 **RESULTS**

156 Of the 176 unique studies identified using MEDLINE and Web of Science, 12 studies met the  
157 inclusion criteria, and their data comparing LM and PCR diagnostic performance were extracted  
158 (Fig. 1). The studies enrolled febrile patients presenting in health clinics in Malaysia (n = 7),  
159 Thailand (n = 2), Indonesia (n = 1), Myanmar (n = 1), and China (n = 1). Among the 12,690 total  
160 patients enrolled across the 12 studies, the pooled percentage positive by PCR was 17% for *P.*  
161 *falciparum*, 24% for *P. vivax*, 38% for *P. knowlesi*, 1.7% for *P. malariae*, and 0.36% for *P. ovale*  
162 (Table 1). The studies varied widely in the percentage positive by PCR across *Plasmodium* spp.,  
163 encompassing a wide range of epidemiological settings and study designs (i.e., criteria for patient  
164 enrollment) in which we estimated LM diagnostic performance.

165



166

167 **Figure 1. PRISMA Flow Diagram.** Flow diagram of the studies identified using MEDLINE and

168 *Web of Science for the systematic review.*

169

170

171 **Table 1. Reported Plasmodium spp. percentage positive by diagnostic method. The percentage**  
 172 **of study participants positive by LM and PCR are reported for each Plasmodium spp. in each**  
 173 **study, along with the study location, year, and total number and type of samples collected. For**  
 174 **Pk and Pm LM percentage of study participants positive, \* indicates that the percentage positive**  
 175 **was computed using a diagnosis of “Pk/Pm.”**

Ref.	Location	Samples	Type	Years	<i>P. falciparum</i>		<i>P. vivax</i>		<i>P. knowlesi</i>		<i>P. malariae</i>		<i>P. ovale</i>	
					PCR	LM	PCR	LM	PCR	LM	PCR	LM	PCR	LM
[15]	Malaysia	960	LM+	2001- 2006	26 (249)	23 (218)	51 (487)	45 (430)	28 (266)	0.0 (0)	0.42 (4)	33 (312)	0.73 (7)	0.21 (2)
[19]	Thailand	1,874	Any Febrile	2006- 2007	41 (762)	37 (687)	64 (1192)	54 (1021)	0.53 (10)	0.0 (0)	1.3 (24)	0.16 (3)	0.96 (18)	0.0 (0)
[16]	Malaysia	189	LM+	2008- 2011	37 (70)	39 (74)	35 (66)	35 (67)	22 (42)	0.0 (0)	1.1 (2)	27 (51)	0.0 (0)	0.0 (0)
[11]	Malaysia	461	LM+	2009- 2011	7.2 (33)	12 (54)	16 (74)	13 (59)	85 (392)	92* (425)	0.87 (4)	2* (425)	0.0 (0)	0.0 (0)
[13]	Malaysia	227	Any Febrile	2008- 2010	42 (95)	41 (92)	41 (92)	38 (87)	16 (36)	0.0 (0)	0.88 (2)	15 (33)	0.044 (1)	0.044 (1)
[21]	China	560	Any Febrile	2008- 2012	28 (159)	28 (156)	51 (288)	49 (276)	0.36 (2)	0.0 (0)	1.6 (9)	0.0 (0)	2.7 (15)	0.0 (0)
[7]	Malaysia	303	PCR+/LM+	2010- 2011	43 (130)	47 (142)	16 (47)	16 (47)	44 (132)	42* (128)	0.66 (2)	42* (128)	0.0 (0)	0.0 (0)
[12]	Thailand	297	Any Febrile	2012	9.1 (27)	3.4 (10)	8.8 (26)	5.1 (15)	0.0 (0)	0.0 (0)	0.34 (1)	0.34 (1)	0.0 (0)	0.0 (0)
[20]	Malaysia	457	LM+	2012- 2013	11 (51)	12 (54)	32 (144)	30 (138)	58 (267)	40 (185)	0.22 (1)	18 (81)	0.044 (2)	0.022 (1)
[17]	Myanmar	90	Any Febrile	2013- 2015	44 (40)	43 (39)	20 (18)	19 (17)	0.0 (0)	0.0 (0)	1.1 (1)	1.1 (1)	0.0 (0)	0.0 (0)
[18]	Indonesia		Any Febrile	2015										
	<i>Batubara</i>	1,270			6.2 (79)	3.4 (43)	10 (131)	6.5 (83)	12 (148)	0.0 (0)	1.2 (15)	0.0 (0)	0.0 (0)	0.0 (0)
	<i>Langkat</i>	544			16 (87)	9.6 (52)	16 (85)	10 (56)	5.9 (32)	0.0 (0)	1.1 (6)	0.18 (1)	0.0 (0)	0.0 (0)
	<i>South Nias</i>	1,917			12 (227)	15 (294)	17 (321)	6.8 (131)	14 (263)	0.0 (0)	5.6 (107)	0.0 (0)	0.0 (0)	0.0 (0)
[14]	Malaysia	3,541	PCR+/LM+	2015-	4.9	4.9	2.5	2.5	92	93*	1.1	93*	0.085	0.0

It is made available under a [CC-BY 4.0 International license](#) .


		2017	(173)	(174)	(87)	(87)	(3255)	(3280)	(40)	(3280)	(3)	(0)
<b>Total</b>	12,690	17	16	24	20	38	32	1.7	34	0.36	0.032	
		(2182)	(2089)	(3058)	(2514)	(4845)	(4018)	(218)	(4316)	(46)	(4)	

176

177

178 After validating on 200 simulated datasets (Fig. S1), we applied our hierarchical latent class  
179 model to the data from the 12 studies identified in the systematic review. Our fitted hierarchical  
180 latent class model captured the variation in the observed data (Fig. S2) and revealed differences  
181 in LM diagnostic performance across *Plasmodium* spp. (Fig. 2). Specifically, we estimated that  
182 the species-level mean sensitivity of LM was 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum*,  
183 40.3% (22.0 – 61.5%) for *P. vivax*, 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 –  
184 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale*. Species-level mean  
185 specificity of LM was consistently high across *Plasmodium* spp. and was estimated at 98.5%  
186 (96.7 – 99.4%) for *P. falciparum*, 98.8% (97.3 – 99.5%) for *P. vivax*, 100% (99.9 – 100%) for *P.*  
187 *knowlesi*, 99.3% (98.0 – 99.8%) for *P. malariae*, and 100% (100 – 100%) for *P. ovale*. These  
188 results were robust to the assumption of PCR as the gold standard (Fig. S4).

189



190

191 **Figure 2. Group-level posterior estimates of LM diagnostic performance. The group-level**


192 **distributions of LM sensitivity (A, C, E, G, I) and LM specificity (B, D, F, H, I) are shown for**

193 *Plasmodium falciparum* (teal; A, B), *Plasmodium vivax* (orange; C, D), *Plasmodium knowlesi*  
194 (purple; E, F), *Plasmodium malariae* (pink; G, H), and *Plasmodium ovale* (green; I, J). Thick  
195 lines are the maximum a posteriori estimates, and thin lines are 25 posterior samples.

196

197 The variance in the hierarchical distributions of LM diagnostic performance in Fig. 2 revealed  
198 the extent of variation across studies, a feature that depended upon both the diagnostic measure  
199 and the *Plasmodium* spp. considered (Fig. 3). In general, for a given *Plasmodium* spp., we  
200 estimated greater variation across studies in LM sensitivity than specificity. For example, for *P.*  
201 *falciparum*, we estimated that logit-transformed standard deviation of LM sensitivity was 1.61  
202 (1.26 – 2.09), suggesting that the range of sensitivities that fell within one standard deviation of  
203 the mean was 12.5 – 78.2%. By comparison, the estimated logit-transformed standard deviation  
204 of LM specificity for *P. falciparum* was 1.48 (1.13 – 1.93), corresponding to a range of  
205 specificities within one standard deviation of the mean of 93.8 – 99.7%. Across *Plasmodium*  
206 spp., study-level estimates of LM sensitivity and specificity for *P. falciparum*, *P. vivax*, and *P.*  
207 *malariae* exhibited greater variation than for *P. knowlesi* and *P. ovale*.

208



209

210 **Figure 3. Site-level posterior estimates of LM diagnostic performance.** The site-level posterior

211 estimates of (A) LM sensitivity and (B) LM specificity are shown for *P. falciparum* (teal), *P.*



212 *vivax* (orange), *P. knowlesi* (purple), *P. malariae* (pink), and *P. ovale* (green). Circles are the  
213 median posterior estimate, and the vertical segment is the 95% credible interval. The horizontal  
214 line is the posterior median of the group-level mean, and the horizontal shaded region is the  
215 corresponding 95% credible interval.


216

217 Because the estimates of LM diagnostic performance varied across the unique studies, we then  
218 assessed its relationship with observed PCR prevalence (Fig. 4). We observed strong, positive  
219 correlations between PCR prevalence and LM sensitivity for *P. falciparum* (Pearson Correlation  
220 Test:  $\rho = 0.66$ ;  $p = 0.01$ ) and *P. knowlesi* ( $\rho = 0.83$ ;  $p = 0.0015$ ) and weaker, positive correlations  
221 for *P. vivax* ( $\rho = 0.40$ ) and *P. ovale* ( $\rho = 0.012$ ), though the latter two were not statistically  
222 significant associations. By contrast, for *P. malariae*, there was a negative correlation between  
223 PCR prevalence and LM sensitivity, though this estimate was also not statistically significant.  
224 Across *Plasmodium* spp., increased PCR prevalence of *P. knowlesi* was associated with reduced  
225 sensitivity of LM for *P. vivax* ( $\rho = -0.58$ ;  $p = 0.029$ ), highlighting a possible source of  
226 misdiagnosis. Additional negative associations were observed between PCR prevalence and LM  
227 sensitivity across *P. falciparum*, *P. knowlesi*, and *P. malariae*—*Plasmodium* spp. that are  
228 commonly misdiagnosed—though these quantities were not statistically significant.

229 Generally, for a given *Plasmodium* spp., PCR prevalence was negatively associated with  
230 LM specificity (Fig. 4B). For *P. knowlesi*, this association was strong and statistically significant  
231 ( $\rho = -0.62$ ;  $p = 0.017$ ), and additional weaker, yet statistically non-significant relationships were  
232 observed for *P. falciparum*, *P. vivax*, and *P. ovale*. The opposite relationship was observed for *P.*  
233 *malariae*, though this quantity was not statistically significant. Across *Plasmodium* spp.,  
234 increased prevalence of *P. malariae* was associated with reduced specificities of LM for *P.*

235 *falciparum* ( $\rho = -0.79$ ;  $p < 0.001$ ) and *P. vivax* ( $\rho = -0.72$ ;  $p = 0.0036$ ), and increased prevalence  
236 of *P. knowlesi* was associated with reduced specificity of LM for *P. malariae*.

237



238

239 **Figure 4. Correlations between Plasmodium spp. fever prevalence and LM diagnostic**

240 **performance.** The correlations between Plasmodium spp. fever prevalence and (A) LM

241 **sensitivity and (B) LM specificity are reported.** The color represents the strength of the

242 **correlation, with red colors denoting positive correlations and blue colors denoting negative**

243 **correlations. ‘\*’ denotes  $p < 0.05$ , ‘\*\*’ denotes  $p < 0.01$ , and ‘\*\*\*’ denotes  $p < 0.001$ .**

244

## 245 DISCUSSION

246 In this systematic review and meta-analysis, we estimated study-level and species-level variation

247 in the malaria diagnostic performance of light microscopy in epidemiological settings with co-

248 circulation of the five Plasmodium spp. that cause human malaria. Our analysis revealed

249 consistently low sensitivity of light microscopy to diagnose Plasmodium spp. infection.

250 Sensitivity of light microscopy was estimated to be considerably lower for *P. knowlesi*, *P.*

251 *malariae*, and *P. ovale* than for *P. falciparum* and *P. vivax*. This suggests that the burden of *P.*

252 *knowlesi*, *P. malariae*, and *P. ovale* in a clinical setting may be appreciably underestimated,  
253 consistent with a recent study of *P. ovale* in health clinics in Kenya [4].

254 Post-hoc analyses revealed relationships between the diagnostic performance of light  
255 microscopy and the epidemiological setting. In general, we noted a positive association between  
256 the PCR prevalence of a *Plasmodium* spp. and the sensitivity of light microscopy for that  
257 *Plasmodium* spp. This supports a phenomenon whereby the more a microscopist encounters  
258 samples of a *Plasmodium* spp. infection in a clinical setting, the more likely they are to  
259 accurately identify the *Plasmodium* spp. causing that infection. By contrast, increased PCR  
260 prevalence of a *Plasmodium* spp. was associated with high false-positive probabilities for that  
261 *Plasmodium* spp. This tendency to misdiagnose malaria infections as what is most commonly  
262 encountered in that clinical setting could lead to ineffective monitoring of less commonly  
263 encountered *Plasmodium* spp., such as *P. knowlesi*, *P. malariae*, and *P. ovale*.

264 The high probabilities of misdiagnosis estimated in this analysis could have important  
265 consequences for malaria treatment and control. Specifically, we observed an association  
266 between increased prevalence of *P. knowlesi* and reduced sensitivity of LM for *P. vivax*. This  
267 suggests that in areas with *P. knowlesi*, infections of *P. vivax* may not be correctly diagnosed and  
268 therefore may not receive radical cure therapy to clear hypnozoites and prevent relapse [25].  
269 Additionally, increased prevalence of *P. malariae* was associated with reduced specificity of LM  
270 for *P. vivax*, indicating that many *P. malariae* infections may be misdiagnosed as *P. vivax*. This  
271 form of misdiagnosis could unnecessarily subject individuals to radical cure therapy, potentially  
272 increasing the risk of acute hemolysis among individuals deficient of the glucose-6-phosphate  
273 dehydrogenase enzyme [26].

274           Routine diagnosis of clinical malaria by light microscopy may prevent effective  
275 monitoring of *P. knowlesi* transmission and burden. We estimated very low sensitivity of LM to  
276 diagnose *P. knowlesi* infections, given the morphological similarities of the parasites to those of  
277 *P. falciparum* and *P. malariae* [3,6] as well as likely delays in familiarity of *P. knowlesi* among  
278 microscopists in the health systems. Sensitivity of LM was improved in settings that allowed for  
279 a “*P. knowlesi/P. malariae*” diagnosis, indicating that further speciation is often not possible.  
280 Although in practice *P. knowlesi* and *P. malariae* infections diagnosed by light microscopy are  
281 confirmed by PCR in many settings [11], *P. knowlesi* infections misdiagnosed as *P. falciparum*,  
282 for instance, would not be subject to confirmatory PCR. This could lead to an underestimate of  
283 *P. knowlesi* burden, affecting epidemiological assessments of *P. knowlesi* infection risk.

284           Our analysis is subject to a number of limitations. Our systematic review may not have  
285 identified all studies with relevant data, including those studies not indexed by MEDLINE and  
286 Web of Science. We limited our review to studies that tested for all five *Plasmodium* spp.  
287 However, studies that included subsets of the five *Plasmodium* spp. could still be informative of  
288 species-level diagnostic performance. Our latent class model assumed conditional independence  
289 of diagnosis across *Plasmodium* spp. Future extensions of this work could account for the  
290 correlation structure of LM diagnosis across the *Plasmodium* spp., due to shared morphologies of  
291 the parasites. Additionally, to address non-identifiability issues, we assumed PCR to be the gold  
292 standard. Although sensitivity analyses revealed that our species-level estimates were robust to  
293 this assumption, future work could jointly estimate the diagnostic performance of both methods,  
294 providing a more complete characterization of misdiagnosis of *Plasmodium* spp. in settings with  
295 co-circulation of multiple *Plasmodium* species.

296

297 **NOTES**

298 *Author Contributions*

299 J.H.H. and T.A.P. conceived of the study. J.H.H. developed the methodology and performed the  
300 systematic review and analyses. J.H.H. and M.E. verified the underlying data. J.H.H., M.E.,  
301 C.K., and T.A.P. interpreted the results. J.H.H. and T.A.P. wrote the initial draft, and all authors  
302 provided comments on the final draft. All authors had access to the underlying data.

303

304 *Disclaimer*

305 The funding sources had no role in the study design, data collection, analysis, interpretation, or  
306 writing of the report.

307

308 *Financial Support*

309 This work was supported by a Graduate Research Fellowship from the National Science  
310 Foundation to J.H.H, a Richard and Peggy Notebaert Premier Fellowship from the University of  
311 Notre Dame to J.H.H, and the National Institute of Allergy and Infectious Diseases [grant  
312 number R21-AI137891] to C.K.

313

314 *Potential Conflicts of Interest*

315 All authors have no conflicts of interest to declare.

316

317 *Acknowledgments*

318 The authors thank Parker Ladwig for helpful advice on conducting a systematic review.

319

320 *Availability of Data and Materials*

321 All code and data to reproduce the analyses can be accessed at

322 [https://github.com/johnhuber/malaria\\_misdiagnosis.git](https://github.com/johnhuber/malaria_misdiagnosis.git).

323

324 **REFERENCES**

- 325 1. Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and  
326 mortality of *Plasmodium falciparum*, 2000–17: a spatial and temporal modelling study. *The Lancet* **2019**; 394:322–331.  
327
- 328 2. Battle KE, Lucas TCD, Nguyen M, et al. Mapping the global endemicity and clinical  
329 burden of *Plasmodium vivax*, 2000–17: a spatial and temporal modelling study. *The Lancet*  
330 **2019**; 394:332–343.
- 331 3. Feachem RGA, Chen I, Akbari O, et al. Malaria eradication within a generation: ambitious,  
332 achievable, and necessary. *The Lancet* **2019**; 394:1056–1112.
- 333 4. Akala HM, Watson OJ, Mitei KK, et al. *Plasmodium* interspecies interactions during a  
334 period of increasing prevalence of *Plasmodium ovale* in symptomatic individuals seeking  
335 treatment: an observational study. *The Lancet Microbe* **2021**; 2:e141–e150.
- 336 5. Whittaker C, Slater H, Nash R, et al. Global patterns of submicroscopic *Plasmodium*  
337 *falciparum* malaria infection: insights from a systematic review and meta-analysis of  
338 population surveys. *The Lancet Microbe* **2021**; :S2666524721000550.
- 339 6. Singh B, Sung LK, Matusop A, et al. A large focus of naturally acquired *Plasmodium*  
340 *knowlesi* infections in human beings. *The Lancet* **2004**; 363:1017–1024.
- 341 7. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM. Limitations of microscopy to  
342 differentiate *Plasmodium* species in a region co-endemic for *Plasmodium falciparum*,  
343 *Plasmodium vivax* and *Plasmodium knowlesi*. *Malar J* **2013**; 12:8.
- 344 8. Guidelines for the Treatment of Malaria. 3rd ed. Geneva: World Health Organization, 2015.  
345 Available at: <http://www.ncbi.nlm.nih.gov/books/NBK294440/>. Accessed 16 December  
346 2020.
- 347 9. Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite,  
348 *Plasmodium knowlesi*. *Clin Infect Dis* **2011**; 52:1356–1362.
- 349 10. Blumberg S, Lloyd-Smith JO. Comparing methods for estimating  $R_0$  from the size  
350 distribution of subcritical transmission chains. *Epidemics* **2013**; 5:131–145.

- 351 11. Barber BE, William T, Dhararaj P, et al. Epidemiology of Plasmodium knowlesi malaria in  
352 north-east Sabah, Malaysia: family clusters and wide age distribution. *Malar J* **2012**;  
353 11:401.
- 354 12. Baum E, Sattabongkot J, Sirichaisinthop J, et al. Common asymptomatic and  
355 submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular  
356 and serological studies: a challenge to malaria elimination. *Malar J* **2016**; 15:333.
- 357 13. Chua KH, Lim SC, Ng CC, et al. Development of High Resolution Melting Analysis for the  
358 Diagnosis of Human Malaria. *Scientific Reports* **2015**; 5:15671.
- 359 14. Cooper DJ, Rajahram GS, William T, et al. Plasmodium knowlesi Malaria in Sabah,  
360 Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the  
361 Human-only Plasmodium Species. *Clin Infect Dis* **2020**; 70:361–367.
- 362 15. Cox-Singh J, Davis TME, Lee K-S, et al. Plasmodium knowlesi malaria in humans is  
363 widely distributed and potentially life threatening. *Clin Infect Dis* **2008**; 46:165–171.
- 364 16. Goh XT, Lim YAL, Vythilingam I, et al. Increased detection of Plasmodium knowlesi in  
365 Sandakan division, Sabah as revealed by PlasmoNex<sup>TM</sup>. *Malar J* **2013**; 12:264.
- 366 17. Han TZ, Han KT, Aye KH, Hlaing T, Thant KZ, Vythilingam I. Comparison of microscopy  
367 and PCR for the detection of human Plasmodium species and Plasmodium knowlesi in  
368 southern Myanmar. *Asian Pacific Journal of Tropical Biomedicine* **2017**; 7:680–685.
- 369 18. Lubis IND, Wijaya H, Lubis M, et al. Contribution of Plasmodium knowlesi to  
370 Multispecies Human Malaria Infections in North Sumatera, Indonesia. *J Infect Dis* **2017**;  
371 215:1148–1155.
- 372 19. Putaporntip C, Hongsriruang T, Seethamchai S, et al. Differential prevalence of  
373 Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. *J*  
374 *Infect Dis* **2009**; 199:1143–1150.
- 375 20. Yusof R, Lau YL, Mahmud R, et al. High proportion of knowlesi malaria in recent malaria  
376 cases in Malaysia. *Malar J* **2014**; 13:168.
- 377 21. Zhou X, Huang J-L, Njuabe MT, Li S-G, Chen J-H, Zhou X-N. A molecular survey of  
378 febrile cases in malaria-endemic areas along China-Myanmar border in Yunnan province,  
379 People's Republic of China. *Parasite* **2014**; 21:27.
- 380 22. Rahim MAFA, Munajat MB, Idris ZM. Malaria distribution and performance of malaria  
381 diagnostic methods in Malaysia (1980-2019): a systematic review. *Malar J* **2020**; 19:395.
- 382 23. Gonçalves L, Subtil A, de Oliveira MR, do Rosário V, Lee P-W, Shaio M-F. Bayesian  
383 Latent Class Models in Malaria Diagnosis. *PLoS ONE* **2012**; 7:e40633.

- 384 24. Carpenter B, Gelman A, Hoffman MD, et al. *Stan*: A Probabilistic Programming  
385 Language. *J Stat Soft* **2017**; 76. Available at: <http://www.jstatsoft.org/v76/i01/>. Accessed  
386 17 July 2021.
- 387 25. Mueller I, Galinski MR, Baird JK, et al. Key gaps in the knowledge of *Plasmodium vivax*, a  
388 neglected human malaria parasite. *The Lancet Infectious Diseases* **2009**; 9:555–566.
- 389 26. Baird JK, Battle KE, Howes RE. Primaquine ineligibility in anti-relapse therapy of  
390 *Plasmodium vivax* malaria: the problem of G6PD deficiency and cytochrome P-450 2D6  
391 polymorphisms. *Malar J* **2018**; 17:42, s12936-018-2190-z.
- 392